STOCK TITAN
  1. Home
  2. Sec-filings
  3. VNRX
  4. [Form 4] VOLITIONRX LTD Insider Trading Activity

VolitionRx (VNRX) CEO receives 42,000 shares from RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

VolitionRx Ltd insider Jasmine Kway reported an equity award tied to previously granted restricted stock units. On January 22, 2026, she acquired 42,000 shares of common stock at $0 per share, reflecting vesting of part of a 140,000-unit RSU grant awarded on March 17, 2025 under the 2024 Stock Incentive Plan. Certain corporate performance goals were met, causing 42,000 RSUs to vest, while the remaining 98,000 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested RSUs are subject to additional time-based vesting in three equal installments of 14,000 units on March 17 of 2026, 2027 and 2028. After this transaction, Kway beneficially owned 245,614 shares of common stock directly and 10,400 shares indirectly through her spouse.

Positive

  • None.

Negative

  • None.
Insider Kway Jasmine
Role CEO - Singapore Volition
Type Security Shares Price Value
Grant/Award Common Stock 42,000 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 245,614 shares (Direct); Common Stock — 10,400 shares (Indirect, By Spouse)
Footnotes (1)
  1. [object Object]
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kway Jasmine
(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD
SUITE 110
(Street)
HENDERSON NV 89014
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO - Singapore Volition
3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/22/2026 A 42,000(1) A $0 245,614 D
Common Stock 10,400 I By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On March 17, 2025, the reporting person was awarded 140,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 42,000 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 14,000 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 98,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.
Remarks:
/s/ Jasmine Kway 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did VolitionRx (VNRX) report for Jasmine Kway?

The filing shows that CEO - Singapore Volition, Jasmine Kway, acquired 42,000 shares of VolitionRx common stock on January 22, 2026. The shares were received at $0 per share in connection with the vesting of restricted stock units under the company’s 2024 Stock Incentive Plan.

How many VolitionRx shares does Jasmine Kway own after this Form 4 transaction?

Following the reported transaction, Jasmine Kway beneficially owned 245,614 shares of VolitionRx common stock directly. In addition, 10,400 shares are held indirectly, reported as owned "By Spouse."

What were the terms of the 140,000 RSU award to VolitionRx CEO Jasmine Kway?

On March 17, 2025, Kway was awarded 140,000 restricted stock units (RSUs) under the 2024 Stock Incentive Plan. The RSUs were subject to corporate performance goals tied to dates on or prior to June 30, 2025 and December 31, 2025, as well as time-based vesting conditions.

Why did only 42,000 of Jasmine Kway’s RSUs at VolitionRx vest?

The footnote explains that certain performance goals were met, which caused the rights with respect to 42,000 RSUs to vest. The rights with respect to the remaining 98,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026.

How will the 42,000 vested RSUs for VolitionRx’s CEO be delivered over time?

The 42,000 vested RSUs are subject to a three-year time-based vesting schedule. They vest in three equal installments of 14,000 units on March 17, 2026, 2027 and 2028. Upon each vesting and settlement, Kway will receive an equal number of VolitionRx common shares.

Were the VolitionRx RSUs granted to Jasmine Kway settled for cash or stock?

According to the disclosure, upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested, indicating stock settlement rather than cash.